Ingevity Corporation
NGVT
$71.64
-$0.39-0.54%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 255.10M | 333.10M | 295.40M | 284.00M | 263.30M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 255.10M | 333.10M | 295.40M | 284.00M | 263.30M |
| Cost of Revenue | 167.30M | 199.20M | 169.00M | 170.60M | 157.10M |
| Gross Profit | 87.80M | 133.90M | 126.40M | 113.40M | 106.20M |
| SG&A Expenses | 41.60M | 44.10M | 42.40M | 43.10M | 38.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 216.30M | 250.30M | 217.70M | 221.40M | 201.80M |
| Operating Income | 38.80M | 82.80M | 77.70M | 62.60M | 61.50M |
| Income Before Tax | -105.30M | 62.20M | -125.70M | 26.80M | 24.10M |
| Income Tax Expenses | -26.50M | 21.40M | 7.10M | 6.30M | 4.50M |
| Earnings from Continuing Operations | -78.80M | 40.80M | -132.80M | 20.50M | 19.60M |
| Earnings from Discontinued Operations | -5.80M | 2.70M | -- | -- | -3.00M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -84.60M | 43.50M | -146.50M | 20.50M | 16.60M |
| EBIT | 38.80M | 82.80M | 77.70M | 62.60M | 61.50M |
| EBITDA | 66.60M | 108.40M | 100.90M | 85.10M | 86.70M |
| EPS Basic | -2.37 | 1.20 | -4.02 | 0.56 | 0.46 |
| Normalized Basic EPS | 0.12 | 1.11 | 1.00 | 0.69 | 3.26 |
| EPS Diluted | -2.37 | 1.17 | -4.02 | 0.56 | 0.46 |
| Normalized Diluted EPS | 0.12 | 1.09 | 1.01 | 0.69 | 3.26 |
| Average Basic Shares Outstanding | 35.70M | 36.31M | 36.42M | 36.38M | 36.32M |
| Average Diluted Shares Outstanding | 35.70M | 36.96M | 36.42M | 36.66M | 36.32M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |